Objective: To explore the expression of long noncoding RNA (lncRNA) LINC01358 in prostate cancer (PCa) and its effect on the proliferation and migration of PCa cells.
Methods: The lncRNA array was used to screen differentially expressed lncRNAs in PCa and the corresponding carcinoma-adjacent normal tissues from 3 patients. The expressions of LINC01358 in the primary PCa, metastatic PCa, and carcinoma-adjacent tissues were compared using the PCa dataset of the Memorial Sloan Kettering Cancer Center (MSKCC). The data obtained were validated by determining the expression of LINC01358 in the PCa and carcinoma-adjacent tissues of another 10 patients by quantitative real time PCR (qRT-PCR). The effects of lncRNA LINC01358 on the proliferation of DU145 cells and migration of PCa cells were detected by MTT and Transwell assay, respectively.
Results: Totally, 79 differentially expressed lncRNAs in the lncRNA array, 36 highly and the other 43 lowly expressed in the PCa tissue. LINC01358 was up-regulated in the cancerous tissue. According to the MSKCC data, the LINC01358 expression was markedly higher in metastatic PCa (5.81±0.19, n = 19) and primary PCa (5.47±0.04, n = 131) than in the PCa-adjacent tissue (5.15±0.07, n = 29) and significantly correlated with postoperative biochemical relapse of the malignancy (P<0.05). qRT-PCR indicated a remarkably higher expression of LINC01358 in the PCa than in the carcinoma-adjacent tissue (6.02±1.12 vs 3.21±0.21, P<0.05). Transfection of the DU145 cells with siRNA significantly decreased the level of LINC01358 and inhibited the proliferation and migration of the PCa cells.
Conclusions: LINC01358 is highly expressed in the PCa tissue and knockdown of LINC01358 may inhibit the proliferation and migration of PCa cells. LncRNA LINC01358 may be involved in the development and progression of PCa and become an index for the early diagnosis as well as a new target for the gene therapy of the malignancy.
目的： 探讨长链非编码RNA（lncRNA） LINC01358在前列腺癌组织中的表达及对前列腺癌细胞增殖和迁移的影响。方法： 选取3对前列腺癌和癌旁组织，进行lncRNA 芯片检测。利用MSKCC前列腺癌患者芯片数据库，比较LINC01358在前列腺癌癌旁、原发性前列腺癌组织和转移性前列腺癌组织中的表达。利用实时荧光定量PCR技术检测10对前列腺癌和癌旁组织中LINC01358的表达验证大数据的结果。采用干扰RNA降低前列腺癌细胞株DU145中LINC01358的表达，MTT检测DU145细胞的增殖，Transwell小室法测定细胞迁移。结果： 在lncRNA芯片中，共有差异表达的lncRNA 79个，其中在肿瘤组织中高表达的有36个，在肿瘤组织中低表达的有43个，LINC01358在前列腺癌组织中高表达。MSKCC前列腺癌患者芯片数据库中，LINC01358在转移性前列腺癌组织（5.81±0.19，n=19）和原发性前列腺癌组织（5.47±0.04，n=131）中的表达高于癌旁组织（5.15±0.07，n=29），且与前列腺癌患者术后生化复发率相关（log-rank P<0.05）。实时荧光定量PCR验证大数据的结果提示，LINC01358在前列腺癌组织（6.02±1.12）中的表达明显高于癌旁组织（3.21±0.21，P<0.05）。应用干扰RNA转染DU145细胞后，LINC01358的表达明显下降。并且转染干扰RNA组和对照组相比，前列腺癌细胞增殖能力和迁移能力明显下降。结论： LINC01358在前列腺癌患者组织中高表达，敲低LINC01358表达可抑制前列腺癌细胞的增殖和迁移。LINC01358可能作为癌基因参与前列腺癌的发生发展，有望成为前列腺癌早期诊断指标及基因治疗的新靶点。.
Keywords: LINC01358; long non-coding RNA; prostate cancer.